Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes

Minze, Molly G.; Will, Kayley; Terrell, Brian T.; Black, Robin L; Irons, Brian K.

doi:10.2174/1573399813666170816142351

Cited by 32 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the recent FDA warning regarding the new adverse side effect of SGLT2 inhibitors, physicians should be aware that Fournier's gangrene can occur in patients with diabetes, especially those with a potential risk of a genital infection (Abstract: Chi WC, August 25, 2016) [1][2][3][4][5][6][7][8][9][10][11][12]. Despite all the positive metabolic effects, reduction in cardiovascular events and delay in the progression of kidney disease of SGLT2 inhibitors, the risk of serious infections should be considered [13][14]. Some studies show that SGLT2 inhibitors raise the risk of developing genital infections and, to a relatively less extent, urinary tract infections due to the pharmacologically-induced glucosuria that promotes the growth of commensal genital microorganisms [15].…”

Section: Discussionmentioning

confidence: 99%

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review

Elshimy¹,

Correa²,

Alsayed³

et al. 2019

Cureus

View full text Add to dashboard Cite

Fournier's gangrene is an extremely rare infection that can occur in immunocompromised patients, especially those with diabetes. Given the severity of this infection and the new associated link to sodium-glucose cotransporter-2 inhibitors, the US FDA recently issued a warning in August 2018. Few cases of Fournier's gangrene have been reported in the literature in diabetic patients taking these oral medications. We report a case of Fournier's gangrene presenting 10 days after a patient with type 2 diabetes started empagliflozin therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review

Elshimy¹,

Correa²,

Alsayed³

et al. 2019

Cureus

View full text Add to dashboard Cite

show abstract

“…2) In contrast, SGLT2, a low affinity, high capacity Na + /glucose cotransporter, is mainly localized to the S1 and S2 segments of the renal proximal tubules and plays a central role in the reabsorption of filtered glucose via the glomeruli. [2][3][4] Given that upregulation of the expression of SGLT2 in type 2 diabetes mellitus (T2DM) increases the maximum reabsorption/transport capacity for glucose, 5) inhibition of SGLT2 represents a novel strategy for the treatment of patients with T2DM.…”

Section: Introductionmentioning

confidence: 99%

<i>In Vitro</i> Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor

Takasu

Yokono

Tahara

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. To date, the only known in vitro pharmacological characteristic of ipragliflozin is its selectivity for SGLT2 over SGLT1, which was previously reported by our group. Therefore, in this study, we investigated other in vitro pharmacological characteristics of ipragliflozin and compared them with those of phlorizin, a naturally occurring SGLT inhibitor. Selectivity of ipragliflozin and phlorizin for human (h) SGLT2 over hSGLT3, hSGLT4, hSGLT5, hSGLT6 and hSodium/myo-inositol (MI) cotransporter 1 (hSMIT1) was examined in Chinese hamster ovary (CHO) cells overexpressing each transporter using specific radioligands. Ipragliflozin had higher selectivity for hSGLT2 than other hSGLTs. Phlorizin showed lower selectivity for hSGLT2 compared to ipragliflozin. Studies using CHO cells overexpressing hSGLT2 demonstrated that both ipragliflozin and phlorizin competitively inhibited SGLT2-mediated methyl-α-D-glucopyranoside (AMG) uptake with an inhibitory constant (K i ) of 2.28 and 20.2 nM, respectively. Ipragliflozin, but not phlorizin, inhibited hSGLT2 in a wash-resistant manner, suggesting that binding of ipragliflozin to hSGLT2 was persistent. These data demonstrate that ipragliflozin is a competitive inhibitor of SGLT2, has high selectivity for SGLT2 over not only SGLT1 but also other SGLT family members, and binds persistently to hSGLT2.

show abstract

“…SGLT-2 inhibitors possess organ-protective effects beyond its glycemic benefits [16]. As large-scale analysis has revealed that patients with cardiometabolic and renal impairments are particularly vulnerable for worst COVID-19 outcome [17], SGLT-2 inhibitors might afford additional vital organ protection in the settings of COVID-19.…”

mentioning

confidence: 99%

SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?

Chatterjee

2020

Primary Care Diabetes

View full text Add to dashboard Cite

Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes

Cited by 32 publications

References 0 publications

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review

<i>In Vitro</i> Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor

SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?

Contact Info

Product

Resources

About